DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Target Cut by Mizuho

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective cut by stock analysts at Mizuho from $14.00 to $12.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price target points to a potential upside of 32.16% from the company’s previous close.

A number of other equities analysts have also issued reports on XRAY. BMO Capital Markets cut their target price on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a research report on Thursday, September 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Barclays lifted their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research report on Monday, August 24th. Piper Sandler reduced their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Friday, October 9th. Finally, Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 10th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $12.77.

DENTSPLY SIRONA Stock Up 2.4%

Shares of NASDAQ XRAY opened at $9.08 on Thursday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. DENTSPLY SIRONA has a 1 year low of $8.32 and a 1 year high of $14.76. The stock’s 50-day simple moving average is $9.95 and its 200-day simple moving average is $10.97. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -3.30, a PEG ratio of 1.13 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the prior year, the business posted $0.52 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts anticipate that DENTSPLY SIRONA will post 1.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth $283,405,000. Paradigm Capital Management Inc. NY purchased a new stake in DENTSPLY SIRONA in the 2nd quarter worth about $39,775,000. The Manufacturers Life Insurance Company acquired a new stake in DENTSPLY SIRONA during the 2nd quarter worth about $1,956,000. Bank of New York Mellon Corp acquired a new stake in DENTSPLY SIRONA during the 2nd quarter worth about $16,408,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in DENTSPLY SIRONA during the 2nd quarter worth about $47,780,000. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.